Last edition
News about " non-cystic fibrosis bronchiectasis "
Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.
Non-cystic Fibrosis Bronchiectasis | 13/08/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members